On June 10, 2021 AUM LifeTech, Inc., a preclinical stage biotechnology company, reported that it has been selected by the National Institutes of Health (NIH) to present an update on their drug development pipeline at 2021 BIO Digital, the premier biotech event (Press release, AUM Lifetech, JUN 10, 2021, View Source [SID1234583853]). The company has leveraged a self-delivering non-viral RNA targeting technology for therapeutic development in oncology, CNS, and infectious diseases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Veenu Aishwarya, Founder and Chief Executive Officer of AUM LifeTech, will present an update on their therapeutic programs. "We are honored to be selected by the NIH to showcase our preclinical developments at BIO 2021. We are very excited about our recent encouraging preclinical data as we move towards the next stages of development," said Aishwarya. "Our therapeutic programs, designed for patients with unmet clinical needs, are now ready for collaborations and strategic alliances to further advance our significantly de-risked preclinical assets," he added.

We are very excited about our recent encouraging preclinical data as we move towards the next stages of development.

AUM LifeTech has developed their preclinical pipeline in cancer immunotherapy with a focus on lung cancer using their proprietary RNA targeting technology. Additionally, their programs in CNS and infectious diseases include therapeutic development for Parkinson’s disease and HIV respectively. AUM LifeTech’s HIV preclinical program is funded by the National Institute of Allergy and Infectious Diseases (NIAID) of the NIH. Their drug development pipeline is based on self-delivering FANA antisense oligonucleotide (FANA ASO) technology.

BIO Digital is scheduled June 10-11 & 14-18, 2021, and AUM LifeTech’s therapeutic developments and insight into their gene silencing technology and preclinical research will be available to registered attendees at 9 am ET on June 10. Attendees at BIO Digital will be able to view the presentation by AUM LifeTech as part of the NIH Innovation Zone before live meetings in the BIO One-on-One Partnering system begin on June 14. To meet with AUM LifeTech at BIO Digital, you can find registration information here.

On June 10, 2021 Phosplatin Therapeutics Inc., a clinical stage pharmaceutical company focused on oncology therapeutics, reported that it has been selected to deliver a presentation on the development program of its lead candidate, PT-112, an immunogenic cell death (ICD) inducer, at 2021 BIO Digital, the premier biotech event (Press release, Phosplatin, JUN 10, 2021, View Source [SID1234583852]). BIO Digital is scheduled June 10-11 and 14-18, 2021, and presentations will be available on-demand throughout the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Robert Fallon, President and Chief Executive Officer, will present the company and its lead clinical candidate, PT-112, a novel small molecule conjugate of pyrophosphate with a pleiotropic mechanism of action that promotes immunogenic cell death (ICD) in the tumor microenvironment. The presentation will be available to registered attendees beginning at 9 am ET on June 10.

"We’re looking forward to presenting PT-112 at BIO so that investors and potential partners can understand our encouraging results to date, which include drug responses in several tumor types of heavily pre-treated patients with advanced metastatic disease," said Fallon. "Data reported from three Phase 1 studies demonstrate feasibility and activity, both as a monotherapy and in combination with PD-L1 immune checkpoint inhibition. We’re currently in Phase 2 clinical trials evaluating PT-112’s optimal dosing for a planned pivotal study, as well as preliminary evidence of efficacy, alongside extensive correlative research using sophisticated liquid sampling technology platforms."

Attendees at BIO Digital will be able to view Phosplatin’s Company Presentation before live meetings in the BIO One-on-One Partnering system begin on June 14. To meet with Phosplatin at BIO Digital, information is available here.

About PT-112

PT-112 is a novel small molecule conjugate of pyrophosphate that possesses a unique pleiotropic mechanism of action that promotes immunogenic cell death (ICD), through the release of damage associated molecular patterns (DAMPs) that bind to dendritic cells and lead to downstream immune effector cell recruitment in the tumor microenvironment. PT-112 represents the best-in-class small molecule inducer of this immunological form of cancer cell death and is currently under Phase II development. Further, PT-112 harbors a property known as osteotropism, or the propensity of the drug to reach its highest concentrations in certain areas of the bone, making it a candidate for treatment of patients with cancers that originate in, or metastasize to, the bone. The first in-human study of PT-112 demonstrated an attractive safety profile and evidence of long-lasting responses among heavily pre-treated patients and won "Best Poster" within the Developmental Therapeutics category at the ESMO (Free ESMO Whitepaper) 2018 Annual Congress. The combination Phase Ib dose escalation study of PT-112 with PD-L1 checkpoint inhibitor avelumab in solid tumors was reported in an oral presentation at the ESMO (Free ESMO Whitepaper) 2020 Virtual Congress. The Phase I study in patients with relapsed or refractory multiple myeloma presented at ASH (Free ASH Whitepaper) is the third completed Phase I study of PT-112. Monotherapy phase 2 development is ongoing in mCRPC, and the PD-L1 combination study is ongoing in a dose confirmation cohort of non-small cell lung cancer (NSCLC) patients.

On June 10, 2021 Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, reported Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a fireside chat at the annual JMP Securities Life Sciences Conference on Thursday, June 17, 2021 at 11:00 AM ET (Press release, Precigen, JUN 10, 2021, View Source [SID1234583851]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Participants may access the live webcasts of the virtual events through Precigen’s website in the Events & Presentations section at investors.precigen.com/events-presentations.

On June 10, 2021 Immunicom, Inc., a global biotech company reported that it is redefining immuno-oncology with breakthrough non-pharmaceutical subtractive immunotherapy treatments designed to preserve quality-of-life while being treated, presented preliminary data from its late-stage, metastatic triple-negative breast cancer (mTNBC) clinical trial at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2021 (Press release, Immunicom, JUN 10, 2021, View Source [SID1234583843]). AACR (Free AACR Whitepaper)’s Annual Meeting is one of the world’s premier scientific gatherings of cancer specialists and researchers, attracting more than 20,000 participants annually.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Immunicom is investigating its FDA-designated breakthrough Immunopheresis therapy, which is a filtration-based subtractive treatment designed to capture sTNF-R proteins that are shed by cancer cells and inhibit a patient’s natural anti-tumor immune activity. Immunicom presented data for the first cohort of mTNBC patients treated with Immunopheresis which showed an 80% decrease of the inhibitory sTNF-R proteins and observed a sustained quality-of-life while on therapy with minimal side effects.

"Current cancer treatments have significant toxicities and can dramatically diminish a patient’s quality-of-life, especially in patients with late-stage disease that have received multiple prior courses of therapy," said Amir Jafri, Immunicom CEO and Founder. "We are studying an innovative emerging therapy which could signal a new era for cancer treatment that employs a novel immunotherapeutic approach which is especially well-tolerated by these fragile patients."

Immunicom’s presentation "Extracorporeal pulldown of soluble TNFRs to unleash the activity of endogenous TNFα in chemorefractory triple-negative breast cancer patients – first-in-human experience" was presented by the study’s Chief Investigator, Piotr Wysocki, MD, PhD, Department Head of Oncology at the Jagiellonian University – Medical College Hospital in Krakow and President of the Polish Society of Clinical Oncology, and will be available online until June 21, 2021, details as follows:
View Source!/9325/presentation/5206

On June 10, 2021 Deep Lens reported a collaboration that will integrate Deep Lens’ artificial intelligence (AI)-based clinical trial screening and matching solution VIPER , into cancer research (Press release, Deep Lens, JUN 10, 2021, View Source [SID1234583842]). VIPER uses proprietary cloud-based technology to facilitate, triage and accelerate the clinical trial recruitment process. The technology will be used at Norton Cancer Institute, the largest provider of cancer care in the Louisville, Ky., area. VIPER will be used to streamline the patient recruitment process by minimizing resource constraints and enabling immediate access to a greater number of clinical trials.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

It is estimated that more than 15,000 oncology clinical trials are actively recruiting patients; however, patient participation in these trials is often as low as three percent. The challenges associated with accrual to cancer-focused research studies are complex and have been magnified by the current global pandemic. VIPER automates the clinical trial screening process and seamlessly matches patients — at the time of diagnosis — to appropriate trials through the ingestion and analysis of customized genomic, electronic medical record and pathology data.

"Deep Lens is committed to making it easier for cancer patients to find trials that may optimize their care and potentially impact the course of their disease," said Greg Andreola, chief revenue officer for Deep Lens. "We are confident that VIPER will help reinforce Norton Cancer Institute’s prominent reputation in Kentucky and Southern Indiana and we look forward to bringing more opportunities for patients to receive access to cutting-edge therapies in development."

Deep Lens’ VIPER integrates directly into electronic medical records such as Epic, molecular data feeds (Caris, Foundation, and in-house labs) and pathology feeds to automatically identify qualified patients for clinical trials. Any practice that utilizes Epic can easily integrate VIPER and all other Deep Lens screening services free of charge.